Lenacapavir to prevent HIV infection: current prices versus estimated costs of production
Lenacapavir could be mass produced for <$100 pppy at launch. Voluntary licensing and multiple suppliers are required to achieve these low prices. This mechanism is already in place for other antiretrovirals. To date, Gilead has not agreed lenacapavir voluntary licences with the Medicines Patent Pool.
Authors
- Jacob Levi (ORCID: https://orcid.org/0000-0003-0206-7121)
- Joseph Fortunak (ORCID: https://orcid.org/0000-0001-5722-2390)
- Victoria Pilkington (ORCID: https://orcid.org/0000-0002-5920-3414)
- Cassandra Fairhead (ORCID: https://orcid.org/0000-0002-5306-6965)
- Junzheng Wang (ORCID: https://orcid.org/0000-0002-7635-9461)
- Andrew Hill (ORCID: https://orcid.org/0000-0002-0606-6890)
- David Roberts (ORCID: https://orcid.org/0000-0001-7520-1446)
- Madison Johnson
- Jevon Layne
Institutions
- Howard University (US)
- University of Liverpool (GB)
- St George’s University Hospitals NHS Foundation Trust (GB)
- University of Oxford (GB)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1093/jac/dkae305
- Citations
- 24
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 9.34